Dr. Bronwyn Ruddy Stall, MD

Dr. Stall practices at Adventhealth Altamonte Springs - HOPD in Altamonte Springs, Florida.

Dr. Stall's NPI, 1124054333, was assigned on June 23, 2006. Dr. Stall graduated from Tulane School of Medicine in 2004. Dr. Stall holds Florida license ME136490.

Dr. Stall's primary practice is Adventhealth Altamonte Springs - HOPD, at 601 E Altamonte Dr, Altamonte Springs, FL 32701.

Dr. Stall's primary practice is Adventhealth Altamonte Springs - HOPD in Altamonte Springs, Florida. Dr. Stall is also affiliated with AdventHealth Orlando. The medical group on file is AdventHealth Medical Group. Dmand AI also links Dr. Stall to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Stall practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Stall's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Stall is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Stall's licenses on file in 2 states: Florida and Virginia.

Dmand AI lists anal cancer radiation, breast cancer radiation, cancer radiation-upper GI, cervical cancer radiation, head & neck cancer radiation and prostate cancer radiation among the conditions Dr. Stall treats.

CMS data shows 1,056 Medicare services from Dr. Stall across 16 procedure codes in 2024, for 168 Medicare patients. Medicare paid $70,585 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 168 Medicare patients who saw Dr. Stall in 2024. The largest group is 65 to 74, with 70 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Stall's median patient age at 72, with 57% women.

In 2024, Dr. Stall wrote 99 Medicare Part D claims for 59 patients. 93% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $78 in total drug cost. In 2023, CMS named 31 claims across 2 drugs.

Dr. Stall accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Stall, published from 2006 to 2010. The most frequent topics are Brain Neoplasms, Glioma and Magnetic Resonance Imaging. Dr. Stall has published most often in Radiat Oncol.

Dmand AI links Dr. Stall to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Intraductal, Noninfiltrating, Prostatic Neoplasms and Breast Carcinoma In Situ.

CMS Open Payments shows 8 general payments to Dr. Stall from 7 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $174.

Dr. Stall graduated from Tulane School of Medicine in 2004. Dr. Stall is a member of AOA and ASTRO.

Dr. Stall is in network with 18 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. HMO plans come from the most carriers, 11. Check the plan with the practice before a visit.